Description

Paclimedak Concentrate for Infusions 6 mg/ml. 5 ml. (30 mg.) №1

Ingredients:

Each ml contains 6 mg of Paclitaxel.

Dosage:

The recommended dosage of Paclimedak concentrate for infusions is determined by the patient’s body surface area and the specific condition being treated.

Indications:

Paclimedak is indicated for the treatment of various cancers including ovarian, breast, lung, and pancreatic cancer.

Contraindications:

Do not use Paclimedak if you have a history of severe hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor EL.

Directions:

Paclimedak is administered intravenously by a healthcare professional in a hospital setting.

Scientific Evidence:

Paclimedak has shown significant efficacy in various clinical trials for the treatment of solid tumors. Studies have demonstrated its ability to inhibit microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells.

Additional Information:

Paclimedak is a widely used chemotherapy drug that has demonstrated effectiveness in improving overall survival rates and quality of life in cancer patients. It is well-tolerated by most patients, with common side effects including neutropenia, neuropathy, and myalgia.

Paclimedak’s pharmacological action involves stabilizing microtubules within the cell, disrupting the normal process of cell division and ultimately leading to cell death. This mechanism makes it an effective treatment for rapidly dividing cancer cells.

Compared to similar drugs, Paclimedak has shown comparable efficacy with a more favorable side effect profile in some patient populations. Its use in combination therapies has also been studied extensively, showing promising results in improving treatment outcomes.